• Veracyte announced 10 Afirma thyroid test abstracts for presentation at the American Thyroid Association meeting, Nov. 4-7, 2026, in Philadelphia.
• The program includes two oral presentations and eight posters, with five studies conducted independently of the company.
• Findings link gene expression to tumor invasion; other studies assess preoperative diagnosis, recurrence risk and potential treatment targets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020900PRIMZONEFULLFEED9867862) on November 02, 2026, and is solely responsible for the information contained therein.